Several studies have found an association between high plasminogen activator inhibitor-1 (PAI-1) levels and myocardial infarction. Whether this is causal or a consequence of atherosclerosis or tissue damage, remains unclear. Homozygous carriers of the 4G allele of the 4G/5G polymorphism in the PAI-1 gene have higher PAI-1 levels compared to carriers of the 5G allele in healthy persons in some studies, but not all. If PAI-1 levels are causally related to myocardial infarction, one would expect more homozygous carriers of the 4G allele among patients, provided that these carriers have high PAI-1 levels among healthy persons in that population. We investigated the distribution of this polymorphism in the "Study of Myocardial Infarctions Leiden" (SMILE), including 331 men with a myocardial infarction and 302 control subjects and measured PAI-1 antigen levels among the latter. Secondly, we looked into the association of cardiovascular risk factors with PAI-1 levels.
Introduction
Plasminogen activator inhibitor-1 (PAI-1) is the major rapid inhibitor of tissue type plasminogen activator (t-PA) (1) . t-PA itself is a physiologic activator of fibrinolysis. PAI-1 deficiency in a child led to a hemorraghic diathesis (2) . A Swedish study suggested that reduced fibrinolytic capacity due to increased plasma levels of a rapid inhibitor of t-PA is important in the pathogenesis of myocardial infarction (3) .
High plasma levels of PAI-1 were independently related to reinfarction within 3 years in 109 men who had survived a myocardial infarction before the age of 45 (4), but not to late reinfarction in a follow-up of 6-years among 127 consecutive young men (5) . Since 1985, several case-control studies found a positive association between plasma levels of PAI-1 activity and antigen, and the risk of myocardial infarction (3, (6) (7) (8) (9) (10) (11) . Other large studies found no association (12) (13) (14) . At best, the association between PAI-1 levels and the risk for myocardial infarction is equivocal. And even if there is truly an association between PAI-1 levels and myocardial infarction, this still does not allow the conclusion of a causal-and-effect relationship between PAI-1 and the risk of myocardial infarction, because of the following complicating factors.
The first issue, which exists even in prospective studies, is the effect of atherosclerosis. If atherosclerosis increases PAI-1 levels, these levels themselves are not a causal risk factor for myocardial infarction, but rather a marker of atherosclerosis. This is not inconceivable as several studies showed preclinical atherosclerosis levels to be associated with elevated PAI-1 antigen and activity levels (15) (16) (17) . Increased PAI-1 mRNA levels were found in atherosclerotic human arteries which supports the hypothesis of PAI-1 levels being a marker of atherosclerosis (18) . The second issue regards the effect of myocardial infarction on PAI-1 levels and appears in cross-sectional and case-control studies. Myocardial infarction is accompanied by tissue damage which may stimulate the production of PAI-1. Elevations in PAI-1 may therefore be a consequence of the disease and not a causal factor. The third issue concerns confounding by cardiovascular risk factors, such as obesity which is known to be related to PAI-1 levels (19) and is simultaneously a risk factor for myocardial infarction.
These difficulties are avoided in a study in which one examines the distribution of a genetic variation of the PAI-1 gene, known to be related to PAI-1 levels in healthy persons. If PAI-1 itself is a causal risk factor, patients with myocardial infarction will more often have the genotype which causes high levels of PAI-1, compared to healthy persons. In this way, we circumvent the problem of atherosclerosis and confounding.
In several studies, the 4G/5G polymorphism in the promoter of the PAI-1 gene was related to plasma PAI-1 activity and antigen levels in healthy persons. Individuals homozygous for the 4G allele had increased PAI-1 levels compared to other individuals with at least one 5G allele (20) (21) (22) (23) (24) (25) (26) (27) .
In this paper we first present the results of the population-based case-control "Study of Myocardial Infarctions Leiden" (SMILE) with respect to the relationship between the 4G/5G polymorphism of the PAI-1 gene and myocardial infarction among 331 men with a first myocardial infarction and 302 controls. Secondly, PAI-1 antigen levels measured in control subjects and the association with the 4G/5G polymorphism of the PAI-1 gene and several cardiovascular risk factors are presented.
Materials and Methods

Patients and Control Subjects
Patients were 331 men with a first myocardial infarction between January 1990 and November 1994, who were below the age of 70. They participated in the population-based case-control "Study of Myocardial Infarctions Leiden" (SMILE). Two of the following three characteristics had to be present in the discharge report or hospital chart to confirm acute myocardial infarction: typical chest pain, electrocardiographic changes typical for myocardial infarction and a transient rise in cardiac enzymes to more than twice the upper limit of normal.
Control subjects were 302 men who had undergone an orthopedic intervention between January 1990 and June 1994, for which they had routinely received prophylactic anticoagulants for a short period. Control subjects were excluded if they had a history of myocardial infarction or had used oral anticoagulants in a 6-month period prior to participation in this study.
Both cases and control subjects were living in the Leiden area and were born in the Netherlands. Excluded were men with renal disease, severe (neuro) psychiatric problems, or a life expectancy less than one year. Every individual completed a questionnaire concerning the presence of cardiovascular risk factors such as smoking and alcohol consumption. For patients all questions referred to the period before their myocardial infarction. The quetelet index was derived by dividing weight (kilograms) by squared height (meters 2 ). Persons were considered obese if their quetelet index exceeded 30 kg/m 2 . Medication use and presence of diabetes were ascertained in an interview with controls and retrieved from discharge letters of patients. A person was classified as hypertensive or hypercholesterolemic when he was taking specific prescription drugs. Full details of the study SMILE have been published elsewhere (28) .
Blood Collection, DNA Analysis and Plasminogen Activator Inhibitor-1 Antigen Assay
Morning fasting blood samples were drawn from the antecubital vein with the person in an upright position. 20 Persons of which a blood sample was drawn, did not fast. Blood in the first tube was allowed to clot and the serum was used for measuring total cholesterol, HDL-cholesterol and triglyceride levels. Following bloodsamples were drawn in two Sarstedt Monovette R tubes containing 0.106 mM trisodium citrate. We used the cells collected after centrifugation of the blood samples, for DNA extraction. The last blood sample was drawn in a CTAD tube (Diatube H, Becton Dickinson) for measurement of PAI-1 antigen and immediately put on ice. Blood of this CTAD tube was centrifuged for 20 min at 3000g at 4°C, after which plasma was aliquoted in two tubes, snap frozen and stored at -80°C. The median time between myocardial infarction or orthopedic intervention and blood collection were 3.5 years (range 0.7 to 5.7 years) and 2.9 years (range 0.6 to 6.0 years) respectively.
High molecular weight DNA was extracted from the white blood cells by a salting-out method (29) . The DNA was stored at 4°C. Amplification of a fragment of the PAI-1 gene was performed using the technique of polymerase chain reaction (PCR) with 1 l genomic DNA and 0.2 units thermostable Taq DNA polymerase (Perkin Elmer, New Jersey, USA) in a Barnstead thermocycler (Biomed GmbH, West-Germany). The nucleotide sequence of the mutant primer at 5' site and the primer at the 3' site were respectively: 5'-GCC CTC AGG GGC ACA GAG AGA GTC TGG CCA-3' and 5'-GCA ATG CAG CCA GCC ACG TG-3'. The initial cycle consisted of a step at 90°C for 4 min; this was followed by 30 cycli of 93°C for 60 sec, 58°C for 60 sec and 70°C for 3 min. This results in a fragment of about 163 bp, which is part of the promoter of the PAI-1 gene. This fragment includes the 4G/5G polymorphism, a single guanosine deletion / insertion variation, 675 base pairs upstream from the start of transcription of the PAI-1 gene, which is located at chromosome 7 (q21.3 -q22) (30) . 5 l of the PCR reactions were digested with 1 unit of BslI restriction enzyme (Biolabs, New England) for 2 h at 55°C. DNA fragments were separated by electrophoresis on 2% agarose gels. The allele coding for 4G gave fragments of 107 bp and 56 bp. The allele coding for 5G gave fragments of 74 bp, 56 bp and 34 bp. Each individual was classified into one of the three genotypes: 4G/4G, 4G/5G or 5G/5G.
Total cholesterol and triglyceride concentrations were measured using enzymatic assays adapted to a Hitachi 747 (Boehringer Mannheim), and high density lipoprotein (HDL)-cholesterol concentration was measured on a Hitachi 911 (Boehringer Mannheim).
PAI-1 antigen was measured in control subjects with an enzyme immunoassay, Biopool Imulyse R PAI-1 (Kordia, the Netherlands). In four control subjects PAI-1 antigen levels measurements were not performed for practical reasons. According to the manufacturer the intra assay coefficient of variation was 5%, the inter assay coefficient was found to be 8.1%. Four individuals in whom extremely high levels of PAI-1 antigen (≥ 200 ng/ml) were measured and who did not have obesity or diabetes were excluded from the statistical analyses. Thus, in the analyses of PAI-1 antigen levels 294 control subjects were included.
Statistical Analysis
Allele frequencies in the cases and control subjects were compared by allele counting and chi-square analysis. The expected genotype distribution was computed using the Hardy-Weinberg equation under equilibrium assumptions. A chi-square test was used to compare the observed numbers of each genotype with those expected for a population in Hardy-Weinberg equilibrium. An odds ratio (OR) was calculated as a measure of relative risk. A 95 % confidence interval (95% CI) was calculated according to the method of Woolf (31) or by using the standard errors of the parameter calculated by logistic regression. Multiple logistic regression was performed to adjust for age. As the PAI-1 antigen level was not normally distributed 10 log transformation was applied. These log transformed values were used in analyses. The PAI-1 antigen levels are presented as geometric means with the appropriate standard deviation (sd) or 95% confidence intervals (CI). Univariate one-way analyses of variance (ANOVA) was used when comparing groups concerning a continuous variable. Distributions of categorical variables were compared by means of the chisquare test. Differences were considered significant at a p-value of <.05. The contribution of various variables to PAI-1 antigen levels was assessed by multiple linear regression analysis. The model with the highest F-value was considered as the best model, i. e. explaining most of the variance of PAI-1 antigen levels.
Results
4G/5G Polymorphism of PAI-1 Gene among Patients and Control Subjects
The characteristics of the 331 patients and 302 control subjects are shown in Table 1 . The mean age of patients was 56.1 (sd 9.0) years compared to 52.9 (sd 12.0) years in control subjects. Established cardiovascular risk factors such as smoking and hypertension were present, more often in patients (respectively 63.1% and 21.5%) than in control subjects (39.4% and 12.6%). In men under the age of 50, these differences were even more pronounced.
The 4G allele frequency was 0.52 (CI 0.47 -0.57) among patients and 0.53 (CI 0.47 -0.59) among control subjects. The distribution of genotypes in both groups was as expected for a sample in Hardy-Weinberg equilibrium. As shown in Table 2 , the relative risks of myocardial infarction for homozygous and heterozygous carriers of the 4G allele were not increased when compared to homozygous carriers of the 5G allele, with odds ratios at or close to unity. Adjustment for age did not affect these results.
In the subgroup of 311 men aged less than 50 years, the 4G allele frequency was 0.56 (CI 0.49 -0.63) among patients and 0.53 (CI 0.46 -0.59) among control subjects. The risk for homozygous carriers of the 4G allele compared to homozygous carriers of the 5G allele was 1.3-fold increased, though not significantly (OR, 1.3; 95% CI, 0.6 -2.9), while for heterozygous carriers no increased risk was found (OR, 1.0; 95% CI, 0.5 -2.1). No differences between genotype distributions were found for men aged 50 years or above, with a frequency of the 4G al-lele of 0.52 in both patients and control subjects. The distribution of genotypes in both patients and control subjects in the younger and older group was as expected for a sample in Hardy-Weinberg equilibrium.
Among non-smokers, the odds ratios adjusted for age were for homozygous carriers of the 4G allele 1.6 (95% CI, 0.8 -3.1) and for heterozygous carriers 1.9 (95% CI, 1.0 -3.5) compared to carriers homozygous for the 5G allele. In contrast, among smokers these odds ratios were respectively 0.7 (95% CI, 0.4 -1.3) and 0.7 (95% CI, 0.4 -1.4). Restriction of the analysis to men without obesity, diabetes, hypertension or hypercholesterolemia, did not change the overall odds ratios presented in Table 2 (i.e. at or very close to unity). Table 1 Characteristics of patients* and control subjects in the "Study of Myocardial Infarctions Leiden" Table 2 Distribution of genotype of the 4G/5G polymorphism of the plasminogen activator inhibitor-1 gene in patients and control subjects Table 3 Plasminogen activator inhibitor-1 (PAI-1) antigen levels in control subjects according to genotype of the 4G/5G polymorphism of the PAI-1 gene Table 4 Association between plasminogen activator inhibitor-1 antigen levels and cardiovascular risk factors in control subjects * p-value of ANOVA comparing log transformed plasminogen activator inhibitor-1 levels † in four persons PAI-1 antigen levels were not measured and four persons were excluded because they had extremely high levels (≥200 ng/ml). Of this group three men were current smokers, seven were regularly alcohol users, two had obesity and one person had diabetes, which explains the difference in numbers with Table 1 .
PAI-1 Antigen Level, 4G/5G Polymorphism and Cardiovascular Risk Factors among Control Subjects
The mean PAI-1 antigen level in 294 healthy controls was 15.8 (sd 2.4 ng/ml), without any statistical difference between genotypes (Table  3) . Six individuals had a PAI-1 antigen level above 100 ng/ml. The results did not change when restriction was made to levels under the 100 ng/ml, nor did exclusion of individuals with known obesity, diabetes, hypertension or hypercholesterolemia affect the results.
Control subjects below the age of 50 years had mean PAI-1 antigen levels of 15.7 (sd 2.4) ng/ml, not significantly different from control subjects of 50 years of age or above, i.e. 15.8 (sd 2.4) ng/ml. In Table 4 it is shown that PAI-1 antigen levels were higher among smokers and former smokers compared to non-smokers (p = .033), and levels seemed to be higher among men using alcohol regularly (p = .057). Only 6 persons had diabetes or hypercholesterolemia and did not show any statistical difference in PAI-1 antigen levels compared to persons without these cardiovascular risk factors. The presence of obesity in 46 individuals was associated with high PAI-1 antigen levels of 33.6 (CI 27.4 -41.1) ng/ml compared to 248 persons without obesity (13.7 (CI 12.4 -15.2) ng/ml) (p < .001). Hypertension in 38 control subjects was associated with a mean PAI-1 level of 21.7 (CI 16.7 -28.1) ng/ml, which was considerably higher than in 256 persons without hypertension (15.1 [CI 13.6 -16.7] ng/ml) (p = .015). All lipids showed a significant association with PAI-1 antigen levels (all p < .001); high cholesterol and triglyceride levels were associated with high PAI-1 antigen levels, and HDL-cholesterol levels showed an inverse association ( Table 5) . The associations between lipids and PAI-1 antigen levels were independent of the 4G/5G polymorphism.
Multiple linear regression was performed with PAI-1 antigen level as the dependent and age, smoking, alcohol use, quetelet index, diabetes, hypertension, (HDL-) cholesterol levels and triglyceride levels as independent variables in various combinations. The model including both age, triglyceride levels and quetelet index explained much of the variance of PAI-1 antigen levels, i. e. 39.2%. The 4G/5G polymorphism did not contribute to this variance.
Discussion
We found no association between the 4G/5G polymorphism of the PAI-1 gene and risk of myocardial infarction. The polymorphism was not related to levels of PAI-1 antigen in healthy men. Former or current smokers, and persons with obesity or hypertension had significant higher PAI-1 antigen levels than those without these cardiovascular risk factors. Both total cholesterol and triglyceride levels were positively, and HDL-cholesterol inversely associated with PAI-1 antigen levels.
Our results confirm those of the Physicians' Health Study (PHS), a cohort study including men aged 40-84 years, where no association was present between the 4G/5G polymorphism of the PAI-1 gene and myocardial infarction and where similar allele frequencies were found (32) . The results of our and other studies (22, 32, 33) contrast with those of a study among 453 patients admitted for investigation of chest pain or suspected coronary artery disease and with those of a Swedish casecontrol study. In the former study, the frequency of the 4G/4G genotype was higher among patients with a history of myocardial infarction (34) . In the latter study, which included 93 men with a first myocardial infarction before the age of 45, the 4G/4G genotype conferred a twofold increased risk of myocardial infarction compared to carriers of the 5G allele (OR, 2.15; 95% CI, 1.17 -3.96) (21) . Restriction to men under the age of 50 in our study SMILE did not confirm these results.
We found no association between genotypes of the 4G/5G polymorphism of the PAI-1 gene and PAI-1 antigen levels in healthy men, which agrees with the results of several studies (23, 35) , but is in disagreement with others (24) (25) (26) (27) 36) . A possible explanation for these different results is that in some populations, but not ours, the 4G/5G polymorphism of the PAI-1 gene is in linkage disequilibrium with a true causal mutation affecting PAI-1 levels. Another possibility is a difference in triglyceride levels between populations. In vitro experiments have shown that both alleles of the 4G/5G polymorphism contain a binding site for a transcriptional activator (A), and that the 5G allele also contains a binding site for a transcriptional repressor (R) that partially overlaps with the A-binding site. Therefore, in the presence of the repressor (R), it is expected that the 4G allele is associated with increased basal gene transcription (20, 37, 38) . More recently, a VLDL response element has been identified, which acts as an activator and is located adjacent to and partly overlaps with the repressor (R)-binding site on the 5G allele. Competition between the transcriptional repressor and the VLDL-induced factor for binding to the 5G allele, may explain the 4G/5G allele specific relation between VLDL triglyceride and PAI-1 levels in plasma (38) . However, it is not known to what extent increasing triglyceride levels will result in removal of the repressor of PAI-1 transcription from the 5G allele and how this will affect plasma PAI-1 antigen levels. It is noted though, that in patients with existing coronary atheroma or with non-insulin-dependent diabetes mellitus homozygous carriers of the 4G allele had very high PAI-1 antigen levels in the presence of high triglyceride levels, compared to homozygous carriers of the 5G allele (39) . In our control group, that on average will have less atherosclerosis, such a relationship was not observed; no differences in the association of PAI-1 antigen with triglyceride levels between genotypes were found. Other studies among healthy persons reported similar findings (22, 24, 35, 36, 40) .
Smokers and men using alcohol had higher PAI-1 antigen levels compared to men without these risk factors, which is also reported in an Italian study among subjects without clinical atherosclerosis (36) . This * p-value of ANOVA comparing log transformed plasminogen activator inhibitor-1 levels † two missing values Table 5 Tertiles of cholesterol, HDL-cholesterol and triglycerides and the association with plasminogen activator inhibitor-1 antigen levels in control subjects is in contrast, however, to several other studies (24, 26, 35) . No differences in PAI-1 antigen levels were found between men with or without diabetes or hypercholesterolemia, though numbers were small, whereas a significant difference was found depending on the presence of obesity or hypertension. Consistent with the results of other studies high triglyceride levels were associated with high PAI-1 antigen levels (14, 26, 35, 36, 40) , as were high cholesterol levels (35, 36) . The negative association between PAI-1 antigen levels and HDL-cholesterol has been described before in patients with angina pectoris (14) . The 4G/5G polymorphism of the PAI-1 gene had no significant contribution to PAI-1 antigen variability, as was found in healthy men in the Stanislas cohort study (24) . In an Italian study the contribution of this polymorphism to PAI-1 antigen levels was small (36) . The association of PAI-1 antigen levels with several cardiovascular risk factors could explain why several studies found a relation between PAI-1 levels and myocardial infarction (3, (6) (7) (8) (9) (10) (11) , and others after adjustment for several of these risk factors did not (13, 14) . We conclude that the 4G/5G polymorphism of the PAI-1 gene is not related to myocardial infarction. As we did not find any association between this polymorphism and PAI-1 antigen levels in healthy persons, we cannot draw any conclusions about the causality of PAI-1 itself for myocardial infarction.
